MDGL
HealthcareMadrigal Pharmaceuticals, Inc. · Biotechnology · $12B
What is Madrigal Pharmaceuticals, Inc.?
Madrigal Pharmaceuticals is a biopharmaceutical company focused on treatments for liver, cardiovascular, and metabolic diseases. Its lead asset targets non-alcoholic steatohepatitis, a condition with significant unmet medical need.
Madrigal advances resmetirom, a liver-directed thyroid hormone receptor-beta agonist in late-stage clinical trials for NASH. The company also develops a backup compound, MGL-3745, and holds a research and commercialization agreement with Hoffmann-La Roche to support its pipeline.
Founded in 2007 and headquartered in West Conshohocken, Pennsylvania.
- Resmetirom – lead NASH therapeutic candidate
- MGL-3745 – backup compound to resmetirom
- Hoffmann-La Roche collaboration for R&D and commercialization
Is MDGL a Good Stock to Buy?
UQS Score rates MDGL as Good overall, reflecting a mixed but noteworthy profile for a clinical-stage biopharmaceutical company.
The Growth pillar stands out as Strong, consistent with a company advancing a late-stage asset in a large, underserved disease area. The Risk pillar also rates Good, suggesting the company's risk profile is relatively managed for its stage.
Quality and Moat both rate Weak, which is typical for pre-profitability biotechs that have yet to establish durable revenue streams or competitive entrenchment.
See the exact pillar breakdown and full financial metrics by signing up for a Pro membership at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does MDGL pay dividends?
No — Madrigal Pharmaceuticals, Inc. does not currently pay a dividend.
MDGL does not pay a dividend. As a clinical-stage company, Madrigal reinvests available capital into research, clinical trials, and commercialization efforts rather than returning cash to shareholders.
When does MDGL report earnings?
Madrigal Pharmaceuticals reports earnings on a quarterly cadence, typical for US-listed equities.
As a clinical-stage company, quarterly results tend to reflect R&D spending and pipeline milestones rather than commercial revenue. Investors typically focus on trial readouts and regulatory updates as key performance indicators.
For the most recent quarter's results, see Madrigal Pharmaceuticals' investor relations page.
MDGL Price History
+369.9% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Madrigal Pharmaceuticals, Inc.?
Based on Madrigal Pharmaceuticals, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Madrigal Pharmaceuticals do?
Madrigal Pharmaceuticals develops treatments for liver, cardiovascular, and metabolic diseases. Its primary focus is resmetirom, a late-stage drug candidate for non-alcoholic steatohepatitis (NASH), a serious liver condition with few approved therapies.
Does MDGL pay dividends?
No, MDGL does not currently pay a dividend. The company is in a clinical stage and directs its resources toward advancing its pipeline rather than distributing cash to shareholders.
When does MDGL report earnings?
Madrigal Pharmaceuticals reports on a standard quarterly schedule. For confirmed dates and the latest results, visit the company's official investor relations page.
Is MDGL a good stock to buy?
UQS Score rates MDGL as Good overall. Growth rates Strong, and Risk rates Good, but Quality and Moat are Weak — reflecting the realities of a pre-commercial biotech. The complete analysis is available to Pro members.
Is MDGL overvalued?
MDGL's Valuation pillar rates Neutral, meaning it does not appear significantly stretched or deeply discounted relative to the UQS framework. Full valuation metrics are available in the Pro view.
What is MDGL's market cap bracket?
MDGL is classified as a large-cap stock, which is notable for a clinical-stage biopharmaceutical company and reflects market expectations around its lead pipeline asset.
Is MDGL a long-term quality indicator?
From a long-term quality standpoint, MDGL's Strong Growth pillar signals meaningful pipeline momentum, but Weak Quality and Moat scores suggest the company has not yet built durable financial or competitive foundations. Pro members can view the full pillar detail.
Who founded Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals was founded in 2007. For details on its founding team and corporate history, the company's official website and public filings are the most reliable sources.
Unlock Full MDGL Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score pillar breakdown across all five dimensions
- ✓Access full financial metrics and trend data
- ✓Compare MDGL against sector peers on quality and growth
- ✓Get the complete analyst view available only to Pro members
Pro Analysis
MDGL — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 49.5 | 16.7 | 37.0 | 80.0 | 77.6 | 56.6 | -0.1 |
| May 20, 2026 | 49.6 | 16.7 | 37.0 | 80.0 | 77.6 | 56.7 | +0.1 |
| May 18, 2026 | 49.5 | 16.7 | 37.0 | 80.0 | 77.6 | 56.4 | 0.0 |
| May 14, 2026 | 49.5 | 16.7 | 37.0 | 80.0 | 77.6 | 56.5 | -0.1 |
| May 12, 2026 | 49.6 | 16.7 | 37.0 | 80.0 | 77.6 | 56.9 | -0.3 |
| May 7, 2026 | 49.9 | 16.7 | 37.0 | 80.0 | 78.3 | 58.4 | -0.1 |
| May 3, 2026 | 50.0 | 16.7 | 37.0 | 80.0 | 78.3 | 59.0 | 0.0 |
| Apr 26, 2026 | 50.0 | 16.7 | 37.0 | 80.0 | 78.3 | 59.1 | 0.0 |
| Apr 23, 2026 | 50.0 | 16.7 | 37.0 | 80.0 | 78.3 | 58.6 | 0.0 |
| Apr 22, 2026 | 50.0 | 16.7 | 37.0 | 80.0 | 78.3 | 58.9 | -4.0 |
MDGL — Pillar Breakdown
Quality
— 16.7/100 (25%)Madrigal Pharmaceuticals, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 80.0/100 (20%)Madrigal Pharmaceuticals, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 77.6/100 (15%)Madrigal Pharmaceuticals, Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 56.6/100 (15%)Madrigal Pharmaceuticals, Inc. trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Moat
— 37/100 (25%)Madrigal Pharmaceuticals, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for MDGL.
Score Composition
Financial Data
More Stock Analysis
How is the MDGL UQS Score Calculated?
The UQS (Unified Quality Score) for Madrigal Pharmaceuticals, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Madrigal Pharmaceuticals, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Madrigal Pharmaceuticals, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.